AMY-101 TFA Cp40 TFA|cas:1789738-04-0|西域试剂

AMY-101 TFA Cp40 TFA,99.83%

产品编号：Bellancom-P1717A| CAS NO：1789738-04-0| 分子式：C₈₃H₁₁₇N₂₃O₁₈S₂.xC₂HF₃O₂

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1717A	￥4000.00	杭州北京（现货）
Bellancom-P1717A	￥9800.00	杭州北京（现货）
Bellancom-P1717A	￥16500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AMY-101 TFA Cp40 TFA

产品介绍

AMY-101 TFA (Cp40 TFA) 是补体 C3 的肽类抑制剂(K_D = 0.5 nM)，可抑制非人类灵长类动物自然发生的牙周炎。AMY-101 TFA (Cp40 TFA) 在 COVID-19 重症肺炎合并全身超炎症模型中具有良好的抗炎活性。

生物活性

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.

体外研究

体内研究

AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis.
AMY-101 can induce a long-lasting anti-inflammatory effect.
AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction.
AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
Dosage:	0.1 mg/site; 50 μL of 2 mg/mL solution.
Administration:	Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Result:	Does not cause irritation in healthy gingiva.

Animal Model:	UUO and sham-operated mice.
Dosage:	1 mg/kg.
Administration:	Subcutaneous injection every 12 h, daily, 7 or 14 days.
Result:	1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
Dosage:	0.1 mg/site; 50 μL of 2 mg/mL solution.
Administration:	Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Result:	Does not cause irritation in healthy gingiva.

Animal Model:	UUO and sham-operated mice.
Dosage:	1 mg/kg.
Administration:	Subcutaneous injection every 12 h, daily, 7 or 14 days.
Result:	1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.